Companies/Edesa Biotech, Inc.

Company profile

Edesa Biotech, Inc.

NASDAQ: EDSA · Healthcare · Biotechnology

Canadian filerHQ Markham, ONCIK 0001540159Reports USD

#1143 of 1,394 Healthcare companies by revenuebottom-decile growth

EA Score

47D

FH 53DQ 44GM 29SS 54

v0.1 · 65/100 weight · provisional

↑ balance-sheet leverage, Altman-Z · ↓ revenue growth (YoY), Piotroski F

Methodology →

Revenue TTM

Rev growth YoY (TTM)

needs 8 qtrs

Net income (FY)

-$7.2M

Employees

Market cap

$66.7M

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Revenue$0$02021

Net income-$7.2M-$7.2M2025

Operating income-$7.9M-$7.9M2025

Total assets$13.5M$13.5M2025

Liabilities$1.8M$1.8M2024

Equity$12.5M$12.5M2025

Revenue trend

FY2015 – FY2021 · USD

$758.7k

FY15

$1.3M

FY16

$50.0k

FY18

FY19

$410.9k

FY19

$328.8k

FY20

FY21

Revenue by segment

Filed disclosures · FY2018

By product

Product100%

By geography

Not disclosed.

The read

Edesa Biotech, Inc. booked $0 in FY2021 revenue, contracting 100% year over year — among the slowest-growing Healthcare companies we track, at a -Infinity% net margin.

Peers · Healthcare

NRx Pharmaceuticals, Inc.23D Scilex Holding Company27D Nakamoto Inc.31D ImageneBio Inc46D

Key facts

CEOPardeep Nijhawan

SectorHealthcare

IndustryBiotechnology

HeadquartersMarkham, ON

ExchangeNASDAQ: EDSA

Employees16

IPO date2010-06-21

Latest filings

8-K2026-06-11 8-K2026-06-05 8-K2026-05-29 8-K2026-05-15 10-Q2026-05-14 8-K2026-05-14 DEF 14A2026-04-03 8-K2026-02-24

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.